argenx SE (EBR: ARGX)

Market Cap	33.42B
Revenue (ttm)	1.71B
Net Income (ttm)	-36.13M
Shares Out	60.37M
EPS (ttm)	-0.61
PE Ratio	n/a
Forward PE	86.66
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,604
Open	550.20
Previous Close	532.20
Day's Range	550.20 - 556.40
52-Week Range	271.00 - 575.80
Beta	0.31
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 31, 2024

About argenx SE

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 1,148
• Stock Exchange: Euronext Brussels
• Ticker Symbol: ARGX

Financial Performance

In 2023, argenx SE's revenue was $1.27 billion, an increase of 187.66% compared to the previous year's $441.01 million. Losses were -$295.05 million, -58.42% less than in 2022.

Financial numbers in USD